SS-31 Research: Elamipretide Trials, Forzinity and Evidence Limits
An SS-31 claim needs a named condition and a measured outcome. Our assessment is that the most informative account includes the biochemical rationale, the unsuccessful primary outcomes in a larger mitochondrial-myopathy trial, and the specific basis for the Forzinity approval. Removing any of those parts produces an incomplete picture.
This profile examines selected human research and official regulatory documents. It is intended for readers trying to understand the evidence behind mitochondrial-health claims, rather than to select an administration schedule or diagnose the cause of fatigue.
Is SS-31 the same research name as elamipretide?
The original older-adult trial identifies SS-31 as a name used in the literature for elamipretide. This connection helps locate studies that do not use SS-31 in their titles. Original publication.
Our recommendation: use both terms in a literature search, then verify the preparation and study setting. A research-name match should not be treated as confirmation that an online vial is the same finished product used in a clinical trial.
Keep the compound, formulation and commercial medicine in separate fields in your notes. Read our molecular-identity guide when a product listing uses an alias without explaining the material. The research-alias guide provides a method for finding the original paper.
What is the mitochondrial rationale?
The FDA prescribing information describes Forzinity as a mitochondrial cardiolipin binder. That is a mechanistic description attached to the medicine’s approved labeling. FDA prescribing information.
Our interpretation: a proposed site of action gives a reason to test a treatment. It does not, by itself, establish how much better someone will walk, whether their fatigue will improve or whether they will live longer. Require the outcome corresponding to the claim.
For a general statement such as “supports mitochondria,” ask the writer to replace it with the actual measurement. Was the study measuring energy-production capacity in a particular muscle, a walking test, a symptom questionnaire or a clinical event? The distinction should remain visible in the headline and conclusion.
Three different questions in the clinical evidence
This original map is an editorial reading aid. It does not depict measured treatment effects.
Did a laboratory measure change in the tested muscle?
Check timing and analysis.
Did walking or fatigue improve against placebo?
Keep primary outcomes prominent.
Which population and endpoint support the approval?
Retain the confirmation requirement.
Our reading rule is to report a result in the card it addresses. Do not use a metabolic measurement as a substitute for a functional result, or a condition-specific approval as evidence for every use discussed online.
The older-adult study: a metabolic signal with important qualifications
A randomized trial enrolled 39 adults aged 60 to 85 who were selected for low mitochondrial function. After a single infusion, the between-group ATP-production-capacity result differed by analysis: P = .055 for absolute change and P = .045 for percentage change. There was no between-group difference at day seven and no significant benefit in the prespecified hand-muscle fatigue-resistance analysis. Roshanravan and colleagues, 2021.
Our interpretation: report both analyses rather than selecting only the favorable P value. Also preserve the selected population, short observation window and specific muscle measurement. This was not a demonstration of better everyday energy in unselected adults.
If a summary emphasizes an additional or post-hoc muscle-performance analysis, ask whether it was the planned analysis and whether the finding was subsequently confirmed. A research signal can justify another experiment without establishing the benefit a consumer wants.
MMPOWER-2: the walking result and fatigue results were different
MMPOWER-2 studied 30 adults with primary mitochondrial myopathy in a four-week crossover comparison. The six-minute walking-distance difference favored elamipretide by 19.8 meters, but the 95% confidence interval ranged from -2.8 to 42.5 meters and the primary result did not reach statistical significance, P = .0833. Selected secondary patient-reported fatigue measures favored treatment. Original trial.
Our interpretation: describe the walking result as uncertain rather than as an established 19.8-meter benefit. Keep the secondary signals, but identify them as secondary. A favorable symptom measure does not change the statistical result of the primary walking comparison.
The practical reading question is what happened when the research program moved to a larger trial. Do not stop the evidence review at the most encouraging early result. Our negative-study explainer describes how confidence intervals and endpoint priority affect a conclusion.
MMPOWER-3: the larger trial did not meet its primary endpoints
MMPOWER-3 randomized 218 participants with genetically confirmed primary mitochondrial myopathy to elamipretide or placebo for 24 weeks. Neither the walking nor total-fatigue primary endpoint was met. The walking-distance difference was -3.2 meters, with a 95% confidence interval from -18.7 to 12.3 meters and P = .69. Original phase 3 report.
Our assessment: this result belongs near the center of a profile discussing functional benefit in that population. It should not be hidden behind mechanism diagrams or an earlier positive secondary outcome. Equally, it should not be rewritten as proof of no biological activity in any setting.
Keep the disease definition attached. An unsuccessful trial in primary mitochondrial myopathy and a regulatory decision concerning Barth syndrome address different clinical programs. Compare the participants, outcome and follow-up before treating them as contradictory statements about one universal use.
What the Forzinity approval actually covers
FDA announced accelerated approval of Forzinity on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms. The approval relied on knee-extensor strength as an intermediate endpoint, with further clinical confirmation required. FDA approval announcement.
FDA’s trial snapshot describes 12 participants in the randomized Barth study, with ten entering the open-label extension and eight participating through extension week 168. All participants were male; the small, selected cohort limited subgroup assessment. FDA trial snapshot.
Our interpretation: retain both the approval and its conditions. Do not describe this as an approval for general fatigue, athletic performance or longevity. Those claims would require their own relevant evidence and regulatory support.
Why the randomized and extension phases must remain separate
The prescribing information states that the randomized Barth trial did not show superiority on walking distance or total fatigue. Knee-extensor strength increases were observed during the open-label extension, rather than during the randomized phase. FDA clinical-studies section.
Our assessment: readers need that distinction to understand the basis and limits of the approval. An extension can provide useful longer-term observations, but it should not be described as maintaining the same placebo comparison as the initial phase.
When reviewing a graph, mark where the controlled period ends. Record how many people contribute data at later visits and which baseline is used. Do not visually connect different phases in a way that implies a continuous randomized comparison.
Safety belongs beside the benefit claim
The Forzinity label warns about hypersensitivity reactions, including serious allergic reactions requiring emergency care. It also describes increased exposure in people with renal impairment. These are product-specific considerations for clinical management. FDA safety and pharmacokinetic sections.
In MMPOWER-2, injection-site reactions were reported in 80% of elamipretide recipients and were mostly mild. Trial safety results.
Our recommendation: assess safety for the actual medicine, route and patient population. Do not use a research profile as a substitute for the full prescribing information or the clinician responsible for care. A research-vial listing should not inherit the medicine’s benefit-risk assessment solely through a shared compound name.
Questions to use when evaluating a new claim
Ask which condition was studied, which preparation was tested, whether the analysis was prespecified and whether the claimed benefit matches the primary result. Ask what the confidence interval permits and how long the participants were observed.
For an approval claim, record the medicine, jurisdiction, indication and date. For a general mitochondrial claim, require a defined outcome before comparing results. Our mitochondrial-research article shows how these questions apply across different compounds.
If the practical concern is persistent fatigue or reduced exercise tolerance, bring that concern and the original source to a qualified clinician. The appraisal priorities here are intended to support that discussion, not to infer a diagnosis or prescribe a trial of treatment.
Frequently asked questions
Does a change in ATP capacity prove that fatigue improves?
Our assessment: require a directly measured fatigue or functional result. The metabolic and functional questions should be evaluated separately.
Does the Barth approval validate every SS-31 product?
Our assessment: no. Keep the approved medicine and indication distinct from an independently sold research material.
Should negative trials be removed after an approval?
Our assessment: no. Preserve them with their population and outcome so readers can understand the complete selected evidence.
Sources and review limits
Updated September 13, 2026. Original trial abstracts, indexed original text and selected FDA document sections were reviewed. Direct PMC access to the older-adult paper encountered a browser challenge; indexed original text supplied the reviewed methods and results. This is a focused review, not an exhaustive systematic review or independent scientific review.